AB INITIO PHARMA PARTNERS WITH ENDO AXIOM TO MANUFACTURE INNOVATIVE NANOTECHNOLOGY-BASED ORAL INSULIN
Sydney, Australia – Ab Initio Pharma, a leading pharmaceutical contract development and manufacturing organisation (CDMO), is excited to announce its partnership with biotech innovator Endo Axiom to advance the development and manufacturing of a groundbreaking nanotechnology-based oral insulin for diabetes treatment.
This collaboration unites Ab Initio Pharma's expertise in Good Manufacturing Practice (GMP) and scale production with Endo Axiom's cutting-edge nanotechnology research led by Dr. Nicholas Hunt, co-founder and CEO of Endo Axiom. Together, the companies aim to transform diabetes care by providing a needle-free, more accessible treatment option.
Dr. Nicholas Hunt commented on the venture, "Our partnership with Ab Initio Pharma marks a significant milestone in bringing our nanotech oral insulin from the lab to the clinic. Their robust GMP manufacturing capabilities are essential for scaling up production safely and efficiently, ensuring that we meet regulatory standards and deliver a high-quality product."
Paul Young, CEO and Head of Production at Ab Initio Pharma, added, "We are thrilled to be at the forefront of manufacturing innovation with Endo Axiom. Our combined efforts are set to fast-track the development of this revolutionary treatment. By focusing on rigorous GMP standards and scalable processes, we are committed to accelerating the path to clinical trials and ultimately, to patients who need it most."
The oral insulin project, which utilises a novel quantum-dot nanocarrier system developed by Endo Axiom, has shown promising results in pre-clinical trials published in Nature Nanotechnology, demonstrating effective absorption and activity in the gut. This breakthrough has the potential to improve the quality of life for millions of people worldwide who require insulin.
Ab Initio Pharma and Endo Axiom are dedicated to adhering to the highest standards of pharmaceutical development, ensuring that this innovative treatment is not only effective but also safe for widespread clinical use.
For more information about Ab Initio Pharma and our projects, please visit our website at www.ab-initio-pharma.com
About Endo Axiom
Endo Axiom is an Australian based Biopharmaceutical firm supported by Proto Axiom, an Australian biotech investment incubator. Endo Axiom is focused on prevention of autoimmune diseases and improving the quality of life of diabetics. We develop biotechnology platforms for the oral delivery of drug and biologics and take these to clinical validation. Our mission is to develop nanotechnology platforms to solve pharmaceutical’s impossible challenges: Oral insulin without hypoglycaemia and immunotherapy without immune suppression for the prevention of type 1 diabetes.
